The text provides unaudited financial information for Merck & Co., Inc., including a condensed consolidated statement of income, balance sheet, and cash flows for the three and nine months ended September 30, 2021. It outlines the company's financial performance, with details on sales, expenses, earnings per share, assets, liabilities, and cash flows. It also discusses the spin-off of Organon & Co. from Merck and recent accounting standards adopted by the company, showing an increase in net income and comprehensive income compared to the previous year. Furthermore, the text presents detailed financial data on various aspects of the company, including loans, fair value of derivatives, income statement impacts of hedging instruments, investments in debt and equity securities, fair value measurements, and financial assets and liabilities measured at fair value. The company also provides tables showcasing figures related to these elements, such as derivative assets and liabilities, gains or losses from derivatives not designated as hedging instruments, and unrealized gains and losses on equity investments, demonstrating a comprehensive look at its financial standing and activities.
Merck recently completed a spin-off of its women's health, biosimilars, and established brands businesses into a new company named Organon. The historical results of these businesses have been reflected as discontinued operations in Merck's financial statements. The company has also engaged in various business development activities, including collaborations and acquisitions. In response to the COVID-19 pandemic, sales have been impacted but have shown growth in certain product lines. Efforts towards cost containment and pricing pressures continue to impact the company's operating results. Key products like Keytruda have seen strong sales growth driven by new indications.

Global sales of various pharmaceutical products by Merck showed mixed trends in the third quarter and first nine months of 2021. Bridion and Prevymis saw growth, while products like Noxafil faced declines due to competition. Zerbaxa sales were suspended, and other products like Simponi and Isentress/Isentress HD experienced declines. Meanwhile, Adempas/Verquvo alliance revenue grew, and Animal Health sales increased. Cost and expenses varied, with restructuring activities being conducted to optimize operations. Overall, income from continuing operations before taxes showed a positive trend in the specified periods.
No significant market risk exposures that impact the disclosures in the 2020 Form 10-K were reported in the statement.
The management of the Company has evaluated the effectiveness of its disclosure controls and procedures over financial reporting and concluded that they are effective as of September 30, 2021. The report contains cautionary statements on forward-looking statements, mentioning the factors that can affect future results. The report advises readers to carefully consider these statements in light of potential risks and uncertainties, and notes that the Company does not assume the obligation to update any forward-looking statement. It also references risk factors described in the Company's filings with the Securities and Exchange Commission for further evaluation. The document emphasizes the importance of understanding and considering various potential risks and uncertainties that could impact actual results compared to expected outcomes.
The text refers to incorporating information called for in legal proceedings by reference to Note 9 in the Financial Statements.
The text discusses the impact of the global COVID-19 pandemic on a company's business, operations, and financial performance as disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020. The Company believes that global health systems and patients are adapting to the pandemic's impacts, though negative effects will persist. It assumes a net unfavorable impact to sales of less than 3% for 2021 related to the Pharmaceutical segment. The estimated negative impact of COVID-19 on sales for the third quarter and nine months of 2021 was around $350 million and $1.3 billion, respectively, all within the Pharmaceutical segment. Operating expenses in the same periods reflected a minor positive effect due to investments in COVID-19 research programs offsetting lower spending in other areas.
The text provides information on unregistered sales of equity securities and issuer purchases for the three months ended September 30, 2021. The issuer purchased a total of 7,770,942 shares at an average price of $74.97 per share, with the total value of shares yet to be purchased under the program being $5,066 million. These purchases were part of a plan approved by the Board of Directors in October 2018 to buy up to $10 billion of Merck's common stock for its treasury.
I'm ready to assist; please provide the text you would like me to summarize for you.
I will summarize the text for you once you provide all the parts.
The text provides a detailed overview of a company's changes in other comprehensive income (loss) for the three months and nine months ended September 30. It covers various components such as derivatives, investments, employee benefit plans, and foreign currency translation adjustments. It also breaks down segment reporting for the Pharmaceutical and Animal Health segments and details the sales of the company's products for the same period. Additionally, it discusses the approval of Koselugo and Welireg for specific medical conditions, sales trends of vaccines like Gardasil/Gardasil 9 and Pneumovax 23, as well as the launch and availability of Vaxneuvance and Vaxelis. The text further explores the growth and decline in sales of drugs, vaccines, and products across various segments like Hospital Acute Care, Immunology, Virology, Cardiovascular, Diabetes, and Animal Health, along with highlighting the related costs, expenses, and financial changes within the business.
The text provided includes details about different exhibits related to Merck & Co., Inc., such as certificates of incorporation, by-laws, certifications of the CEO and CFO, XBRL documents, and a cover page interactive data file. It also includes signatures from company executives for compliance with the Securities Exchange Act of 1934.
